A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

NCT03303495 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms

Interventions

BIOLOGICAL: Bevacizumab
DRUG: CPT-11
DRUG: 5-FU Bolus
DRUG: 5-FU Infusion
DRUG: l-LV (dl-LV)

Sponsor

Sun Yat-sen University